Search

Your search keyword '"de Marinis, F."' showing total 25 results

Search Constraints

Start Over You searched for: Author "de Marinis, F." Remove constraint Author: "de Marinis, F." Journal journal of clinical oncology official journal of the american society of clinical oncology Remove constraint Journal: journal of clinical oncology official journal of the american society of clinical oncology
25 results on '"de Marinis, F."'

Search Results

1. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

2. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

3. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

4. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.

5. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.

6. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

7. Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.

8. Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

9. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

10. EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.

12. Reply to S. Barni et Al, K.R. Dearing et al, and N. Murray.

13. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

14. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

15. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

16. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

17. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

18. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

19. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

20. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

21. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

22. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

23. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.

24. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.

25. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Catalog

Books, media, physical & digital resources